How Is the Market Behaving: Market Take & Reflection
The biopharma market is clearly shifting. In the past, success often meant building a full-scale commercial operation in anticipation of the big product launch. Today, emerging biopharma companies are recognising that what they truly need isn’t big head-count early, but agile, experienced leadership that can move fast, build structure, and hand off cleanly.
A new commercial model for biopharma
Emerging biopharma firms often face a classic tension: finite capital + long lead times + big market opportunity. Commercialisation is no longer a “once we’re approved, then we build” process. Instead, the commercial journey begins
well before approval — months, even years ahead. Industry thought-leaders emphasise this: for example, one article states that “approval is just the start, not the end, of the commercialisation journey.”
DrugPatentWatchmckinsey.com
What does this mean in practice?
- Firms are realising they don’t need to hire full-time executives months ahead of launch when they haven’t yet matured the infrastructure or business model — instead they engage fractional or advisory leadership to set the direction, build the scaffolding, and then transition to full-time as scale demands.
- This approach can preserve capital, reduce overhead, improve flexibility and reduce post-approval lag (the time between approval and commercial ramp).
- The result: commercial readiness that aligns with global market access, reimbursement, diagnostics, patient identification and launch execution — rather than a full team sitting idle or mis-aligned.
What the data shows
Let’s back that up.
- A recent study by McKinsey & Company indicates that first-time launchers (companies launching their first new molecular entity) now generate about 40 % of new assets submitted for approval between 2018-2023 — up from significantly lower levels in prior years. mckinsey.com
- That same McKinsey study reports that these first-time launchers invest around US$80–100 million annually in SG&A beginning at launch year. mckinsey.com
- On the fractional leadership side: industry articles highlight the value of a “fractional CMO” (Chief Marketing/Commercial Officer) or equivalent executive in biopharma: “The Fractional CMO model provides … flexible, high-impact leadership without the full-time cost.” Lean Creative Marketing
- A case-study of biopharma companies engaging fractional CMOs illustrates how this model preserves capital while advancing key strategic and operational milestones. medixteam.com
- Additionally, some consulting firms emphasise that enterprise-transformation roadmaps in biopharma must define 6-12 month non-negotiable outcomes, including launch readiness, monetisation models, commercial/market-access readiness, in order to extend runway and reduce risk. Independent Management Consultants
What this shift means in practice
In practice, this market behaviour shows up in several key tactics:
Start commercialisation planning early
Many companies are shifting to begin commercial or market-access build 6–12 months before approval (or even earlier). The point: you cannot wait until approval to start payer negotiations, diagnostics build, patient-identification infrastructure or go-to-market design. (While I did not find a precise public number for “6–12 months before approval” in all cases, consulting benchmarks and readiness frameworks advocate for meaningful pre-approval planning.)
Use fractional or interim leadership
Rather than hiring a full-time Senior Commercial Executive six months ahead of launch (which may be expensive and risk idle capacity), companies engage senior operators on an interim, fractional or advisory model to create the systems, frameworks and vendor ecosystem, set strategy and hand over once the launch phase demands full scale.
Smooth transition to permanent leadership
The idea is not “fractional forever” — but rather: use fractional leadership to build the launch-capability foundation, then transition to a full-time commercial team when the timing and resources are aligned. This helps avoid premature staffing, locked-in high costs, mis-alignment of roles and infrastructure build just for the sake of build.
Alignment is everything
The commercial model is shifting from “who can hire fastest” to “who can align first” — meaning: aligning strategy (clinical, regulatory, access, commercial), aligning vendors and service providers, aligning leadership roles, and aligning timing of build with key inflection points.
Capital discipline + flexibility
For emerging biopharma companies, capital preservation is critical. The market is reflecting awareness that large upfront hires may not deliver optimal return. By using more agile models, companies maintain financial flexibility, preserve runway, and can scale when the data/market risk is lower.
Why the market is forcing this shift
- Biopharma companies face increasingly compressed timelines, higher cost pressure, and more complex reimbursement/access environments. The window to first-mover advantage is narrower.
- Jumping into full-scale commercial build too early can lead to inefficiencies: high fixed costs in R&D-heavy companies, misallocated resources, under-utilised team members and misalignment between commercial efforts and product readiness.
- The vendor/outsourced economy is richer now: thanks to more specialised service providers, fractional executive talent pools, and more mature commercial frameworks for emerging biopharma, companies can access what used to require big organisations—but in a leaner way.
- Investors and boards are more disciplined: there’s more awareness that building for scale before readiness is risky and burn-heavy. The behaviour of the market is to reward companies that show structured, phased, efficient commercial build rather than pre-emptive hiring sprees.
Some numbers to highlight
- Emerging launchers (first-time launch companies) now account for ~40 % of new assets submitted.mckinsey.com
- First-time launchers invest ~US$80–100 million annually in SG&A in the launch year.mckinsey.com
- The fractional CMO-model is increasingly recognised in biopharma/life sciences as delivering strategic speed + flexibility at lower cost.Lean Creative Marketing
- Launch readiness and non-negotiable outcomes must often be defined for the 6–12 month horizon ahead of major inflection points (e.g., approval).Independent Management Consultants
Reflections for biopharma leadership
If you’re leading a biopharma (or advising one) in this market, here are reflections to internalise:
Don’t wait until approval. Build the roadmap now, 6–12 months ahead of key inflection points at least.
If not full-time, consider fractional or interim leadership to set the foundation of commercial strategy and execution.
If you hire big ahead of readiness, you risk burning runway on under-utilised capacity. If you build too late, you risk missing market opportunities.
We live in a world of evolving modalities, reimbursement complexities, diagnostics-enabled access, and shifting commercial dynamics. The organisational model must support flexibility, vendor orchestration, and phasing.
A clean hand-off plan is often overlooked. Make sure you know when and how you flip from “foundation phase” to “scale phase”.
For example: if approval is two years out, investing heavily in a full sales force now may not be optimal. But building strategy, vendor partnerships, payer engagement, diagnostic flows and commercial segmentation now may be smart.
Conclusion
The biopharma commercial market is behaving differently — smarter, leaner, more strategic. Companies that adapt to this behavioural shift will be better positioned for success in a landscape where time-to-market, patient access, capital discipline and alignment matter more than ever.
In short: It’s no longer about who can hire fastest — it’s about who can align first.
